An anti-EphA3 antibody–drug conjugate (ADC) based on the IIIA4 mAb attached to the microtubule antagonist maytansine (IIIA4-USAN) proved successful in eliminating GBM cells in vitro and inhibiting development of several GBM tumour types in mice compared to the naked antibody [43]. This evidence concerns the gene EPHA3 and neoplasm.